BioUtah News
-
Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology
Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus…
-
Canary Speech Launches Canary Ambient™ Continuous Monitoring to Address Workplace Violence in Healthcare
AI-powered voice analysis expands to detect verbal aggression and prevent nurse burnout through real-time vocal biomarker technology, enhancing…
-
Owlet™ Secures CDSCO Approval for Dream Sock® and Plans 2026 Expansion into India
Owlet expands its global footprint, entering one of the world’s most promising digital health markets, with CDSCO-approved technology.
-
NUSANO AND ARICEUM THERAPEUTICS ANNOUNCE MULTI-ISOTOPE SUPPLY AGREEMENT
AGREEMENT INCLUDES ACTINIUM-225 (AC-225) AND LUTETIUM-177 (LU-177) TO SUPPORT ARICEUM’S THERAPEUTIC PROGRAMS
-
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue…
-
Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Expands to Abu Dhabi
-
Leash Bio Announces Multi-Target Agreement with Monte Rosa Therapeutics
Leash Bio Announces Multi-Target Agreement with Monte Rosa Therapeutics
-
Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care.
-
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care.
-
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
-
Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™
BioSeeker mapped more than 10,000 isolates and identified targetable regions that provide 100% strain coverage across the viral…
-
Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies
Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
